Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 1.00 |
| ▸ | JAK1 | P23458 | 17/20 | 1.00 |
| ▸ | JAK3 | P52333 | 16/20 | 1.00 |
| ▸ | TYK2 | P29597 | 15/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22511745 | 0.95 | JAK2 (0.90) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL3727924 | 0.91 | JAK2 (0.83) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2798308 | 0.90 | JAK2 (0.81) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2798300 | 0.90 | JAK2 (0.83) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL22511818 | 0.89 | JAK2 (0.80) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2797486 | 0.87 | JAK2 (0.77) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2800323 | 0.87 | JAK2 (0.77) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL9100115 | 0.85 | JAK2 (0.75) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL16682502 | 0.85 | JAK2 (0.73) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2797487 | 0.84 | JAK2 (0.72) | JAK2JAK1JAK3TYK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | claimed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.